All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 35 points (-0.2%) at 17,589 as of Tuesday, Oct. 27, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 752 issues advancing vs. 2,254 declining with 128 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is down 0.4%. Top gainers within the industry include

United Therapeutics

(

UTHR

), up 9.5%,

Shire

(

SHPG

), up 7.1%,

Allergan

(

AGN

), up 3.3%,

Alexion Pharmaceuticals

(

ALXN

), up 2.4% and

AbbVie

(

ABBV

), up 2.0%. A company within the industry that fell today was

Novartis

(

NVS

), up 2.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Merck

(

MRK

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Merck is up $0.54 (1.0%) to $53.46 on average volume. Thus far, 5.8 million shares of Merck exchanged hands as compared to its average daily volume of 13.3 million shares. The stock has ranged in price between $52.78-$54.10 after having opened the day at $53.76 as compared to the previous trading day's close of $52.91.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $148.9 billion and is part of the health care sector. Shares are down 6.9% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

TheStreet Recommends

. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Biogen

(

BIIB

) is up $10.70 (3.9%) to $285.30 on average volume. Thus far, 1.7 million shares of Biogen exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $275.11-$285.97 after having opened the day at $276.00 as compared to the previous trading day's close of $274.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $61.7 billion and is part of the health care sector. Shares are down 18.4% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Biogen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Pfizer

(

PFE

) is up $0.53 (1.6%) to $34.69 on heavy volume. Thus far, 21.5 million shares of Pfizer exchanged hands as compared to its average daily volume of 27.3 million shares. The stock has ranged in price between $34.68-$35.45 after having opened the day at $35.01 as compared to the previous trading day's close of $34.16.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $210.0 billion and is part of the health care sector. Shares are up 9.3% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).